Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Carl Barrett

Showing results (181-190 of 210) with videos related to

Pageof 21
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 16, 2025
Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinomaRobert L Hollis, Michael Churchman, Graeme R Grimes, et al.
British Journal of Cancer|November 3, 2018
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistryGemma N Jones, Claire Rooney, Nicola Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient StratificationRobert L Hollis, Alison M Meynert, Caroline O Michie, et al.
British Journal of Cancer|October 19, 2021
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage responseSophie E Willis, Claudia Winkler, Martine P Roudier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2023
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURAJhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular CharacterizationStephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer modelsLyuba Varticovski, Melinda G Hollingshead, Ana I Robles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I TrialCostanza Paoletti, Gaia Schiavon, Emily M Dolce, et al.
NPJ Digital Medicine|December 15, 2025
H&E-based MSI/MMR testing with AI in colorectal cancer: a multi-centred blinded evaluationCher Bass, Foivos Ntelemis, Julian Schmidt, et al.
Human Mutation|December 8, 2017
An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practiceGillian Ellison, Miika Ahdesmäki, Sally Luke, et al.
Pageof 21

Showing results (181-190 of 210) with videos related to

Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|February 16, 2025
Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinomaRobert L Hollis, Michael Churchman, Graeme R Grimes, et al.
British Journal of Cancer|November 3, 2018
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistryGemma N Jones, Claire Rooney, Nicola Griffin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient StratificationRobert L Hollis, Alison M Meynert, Caroline O Michie, et al.
British Journal of Cancer|October 19, 2021
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage responseSophie E Willis, Claudia Winkler, Martine P Roudier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2023
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURAJhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular CharacterizationStephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer modelsLyuba Varticovski, Melinda G Hollingshead, Ana I Robles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I TrialCostanza Paoletti, Gaia Schiavon, Emily M Dolce, et al.
NPJ Digital Medicine|December 15, 2025
H&E-based MSI/MMR testing with AI in colorectal cancer: a multi-centred blinded evaluationCher Bass, Foivos Ntelemis, Julian Schmidt, et al.
Human Mutation|December 8, 2017
An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practiceGillian Ellison, Miika Ahdesmäki, Sally Luke, et al.
Pageof 21